Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02043847 · ClinicalTrials.gov registry record · Phase 1
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
A Phase 1 study of Multiple Myeloma, Relapsed and Multiple Myeloma, Refractory to Standard Treatment, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT02043847 is a Phase 1 study of Multiple Myeloma, Relapsed and Multiple Myeloma, Refractory to Standard Treatment that has completed, run by University of Illinois at Chicago. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02043847, a Phase 1 study of Multiple Myeloma, Relapsed and Multiple Myeloma, Refractory to Standard Treatment, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan. In addition to Melphalan, the conditioning will include targeted total marrow irradiation (TMI). This is a conventional 3+3 phase I trial with increasing doses of TMI from minimum 3Gy to Maximum 9Gy.
Conditions Studied
Interventions
- DRUG Melphalan
- RADIATION Total Marrow Irradiation
- DRUG Filgrastim (G-CSF)
- PROCEDURE Autologous transplant
Study Locations (1)
Illinois
- University of Illinois Cancer Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2014-01-14 |
| Est. Completion | 2016-09-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02043847
The ClinicalTrials.gov registry entry for NCT02043847 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Myeloma, Relapsed appearing as the primary indexed condition, and to 4 interventions - of which Melphalan is the first listed.
NCT02043847 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02043847 about?
NCT02043847 is a clinical study titled "TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)". In this phase I trial, patients with relapsed or refractory multiple myeloma will receive standard autologous stem cell transplant conditioned with high dose melphalan. In addition to Melphalan, the conditioning will include targeted total marrow irradiation (TMI). This is a conventional 3+3 phase I...
What is the current status of trial NCT02043847?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2014-01-14. Estimated completion is 2016-09-14.
What conditions does trial NCT02043847 study?
This clinical trial studies the following conditions: Multiple Myeloma, Relapsed, Multiple Myeloma, Refractory to Standard Treatment.
What interventions are being tested in trial NCT02043847?
The interventions under investigation include: Melphalan (DRUG), Total Marrow Irradiation (RADIATION), Filgrastim (G-CSF) (DRUG), Autologous transplant (PROCEDURE).
Who is sponsoring clinical trial NCT02043847?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02043847 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Multiple Myeloma, Relapsed
All registered trials for this condition
Multiple Myeloma, Refractory to Standard Treatment
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.